Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2026
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
Amara C, Piyarathna D, Kamal A, Chan Y, Kami Reddy K, Ambati C, Hassan M, Shriwas P, Gandhi T, Jain A, Gangnus T, Popli P, Borkar R, Kang S, Summers S, Putluri V, Grimm S, Venkatesh S, Song N, Seeley E, Hedlich-Dwyer J, Chen S, Mahajan N, Jain A, Dobrolecki L, Wells G, Villanueva H, Li J, Liu X, Bollag R, Malovannaya A, Jung S, Lee H, Asangani I, Terris M, Creighton C, Ballester L, Karanam B, Liu S, Lee M, Raju R, Siddiqui M, Eberlin L, Kommagani R, Sreekumar A, Gao J, Young N, Hodges H, Coarfa C, Gassman N, Lerner S, Lotan Y, Putluri N. Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Letters 2026, 653: 218562. PMID: 42092682, DOI: 10.1016/j.canlet.2026.218562.Peer-Reviewed Original ResearchDNA-binding transcription factorsFatty acid biosynthesisCancer cell survivalFatty acid synthesisElevated fatty acid levelsCigarette smokingBladder cancer cellsBladder cancerTumor growthAcid biosynthesisReductive carboxylationMetabolic rewiringTranscription factorsHistone acetylationDNA repairBladder cancer progressionEpigenetic alterationsAcid synthesisMetabolic shiftCarbon sourceMetabolic pathwaysCell survivalFASN inhibitorsBladder tumor growthCancer cellsLeveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer
Kamal A, Putluri V, Gandhi T, Ambati C, Amara C, Kami Reddy K, Spradlin M, Koirala A, Jorvekar S, Grimm S, Fu D, Parsawar K, Jong F, Beecher C, Sen S, Lerner S, Siddiqui M, Lotan Y, Eberlin L, Sreekumar A, Coarfa C, Putluri N. Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer. Cancer & Metabolism 2026, 14: 8. PMID: 41923172, PMCID: PMC13040883, DOI: 10.1186/s40170-026-00427-4.Peer-Reviewed Original ResearchComprehensive metabolic profilingUntargeted metabolomicsBladder cancerMS/MS spectral libraryOrbitrap mass spectrometryNon-muscle-invasive bladder cancerMetabolite annotationMass spectrometryIdentification of novel pathwaysMetabolic landscapeTherapeutically targetable pathwaysDevelopment of precision diagnosticsMuscle-invasivePredictive biomarkersPrognostic valueMetabolic markersMetabolic signaturesMetabolic vulnerabilitiesMetabolomicsSpectral libraryNormal/benign samplesTherapeutic strategiesCancer progressionCancerEarly detectionEnfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Singh P, Lerner S. Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy. The New England Journal Of Medicine 2026 PMID: 41707168, DOI: 10.1056/nejme2515777.Peer-Reviewed Original ResearchInterdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, De Bari B, Dressler M, Engeler D, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler T, Klein J, Laouiti M, Lauffer D, Lerner S, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora P, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel R, Templeton A, Vogl U, Wettstein M, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer. Bladder Cancer 2026, 12: 23523735251410823. PMID: 41550985, PMCID: PMC12811584, DOI: 10.1177/23523735251410823.Peer-Reviewed Original ResearchTrimodality therapyBladder cancerRadical cystectomyFollow-upPersonalized follow-up schedulesRisk-adapted follow-upMuscle-invasive bladder cancerNon-metastatic bladder cancerNational multicentre cohort studyFollow-up durationFollow-up regimensFollow-up protocolFollow-up scheduleMulticentre cohort studyConsensus meetingFollow-up strategiesFunctional follow-upTrimodality treatmentCurative intentOncological surveillanceRadiation oncologyUsage of patientsFunctional complicationsCurative treatmentTreatment optionsAlopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series
Dadabhoy A, Doshi C, Zahir M, Ladi-Seyedian S, Escobar D, Xia L, Schuckman A, Anderson C, Kates M, Agarwal P, Lerner S, Chamie K, Weizer A, Daneshmand S. Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urologic Oncology Seminars And Original Investigations 2026, 44: 110984. PMID: 41529351, DOI: 10.1016/j.urolonc.2025.12.020.Peer-Reviewed Original ResearchConceptsNonmuscle invasive bladder cancerSide effect profilePostoperative doseBacillus Calmette-GuerinUnderreported side effectPost-TURBTHair lossBladder cancerCases of bladder perforationIntravesical bacillus Calmette-GuerinNonmuscle-invasive bladder cancerMulti-institutional case seriesInvasive bladder cancerCancer referral centerProspective multicenter studyFollow-up visitIncidence of alopeciaBladder perforationGemcitabine therapyTransurethral resectionIntravesical gemcitabineUrinary symptomsUrologic oncologistsReferral centerMulticenter study
2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations
Cheng H, Callis S, Yu E, Delacroix S, Sokolova A, Tangen C, Lerner S, Dorff T, Lin D. Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. European Urology Focus 2025, 12: 16-18. PMID: 41354605, DOI: 10.1016/j.euf.2025.11.011.Peer-Reviewed Original ResearchLocalized high-risk prostate cancerHigh-risk prostate cancerPhase 2 studyNeoadjuvant carboplatinBRCA1/2 mutationsProstate cancerPathologic complete response rateComplete response rateGermline BRCA1/2 mutationsPhase 2 trialSurvival outcomesChemotherapy agentsClinical trialsResponse rateCarboplatinSWOGCancerMutationsBRCA1/2ChemotherapyPatientsGermlineEndpointSurvivalTrialsSystemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.
Sadeghi S, Lara P, Necchi A, Gill P, Flaig T, Lerner S, Aron M, Daneshmand S. Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncology Practice 2025, op2500464. PMID: 41252668, DOI: 10.1200/op-25-00464.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerNeoadjuvant systemic therapyPathological complete responseClinical complete responseSystemic therapyOverall survivalCarcinoma in situRadical cystectomyComplete responseBladder cancerSurgical volumeNeoadjuvant cisplatin-based chemotherapyPatients treated with RCMuscle-invasive urothelial carcinomaCohort analysisOutcomes of systemic therapyStandard-of-care treatmentImpact of surgical volumeBladder preservation strategiesPerioperative systemic therapyAdjuvant systemic therapyMuscle-invasive diseaseCisplatin-based chemotherapyMedian Follow-UpNational Cancer DatabaseBladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer
Dyrskjøt L, Black P, Lerner S, Theodorescu D. Bladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer. Bladder Cancer 2025, 11: 23523735251384859. PMID: 41140788, PMCID: PMC12552773, DOI: 10.1177/23523735251384859.Commentaries, Editorials and LettersIntermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Li R, Hensley P, Babjuk M, Bukavina L, Psutka S, Lerner S, O'Donnell M, Lotan Y, Bree K, Redorta J, McConkey D, Lee B, Mariappan P, Mertens L, Soloway M, Svatek R, Tan W, Williams S, Gupta S, Buckley R, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. European Urology Oncology 2025, 8: 1685-1695. PMID: 41076366, DOI: 10.1016/j.euo.2025.08.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational Bladder Cancer GroupNon-muscle-invasive bladder cancerBladder cancer groupClinical trial designTreatment burdenPatient-reported outcomesCancer groupTrial designAdjuvant intravesical treatmentPatient careDelphi processClinical careRisk scoring systemCancer expertsRandomized Controlled StudyClinical trial developmentStandard of careCareIntravesical treatmentPerioperative chemotherapyTransurethral resectionIndolent courseLG tumorsBladder tumorsActive surveillance69Testing cabozantinib with or without atezolizumab in patients with advanced papillary kidney cancer (NCT05411081)
Maughan B, Plets M, Pal S, Ged Y, Tangen C, Vaishampayan U, Lerner S, Desai A. 69Testing cabozantinib with or without atezolizumab in patients with advanced papillary kidney cancer (NCT05411081). The Oncologist 2025, 30: oyaf276.070. PMCID: PMC12509857, DOI: 10.1093/oncolo/oyaf276.070.Peer-Reviewed Original ResearchProgression-free survivalCombination therapySingle-arm studyDose reductionImmune therapyRandomized studyComparison of progression-free survivalClinical trialsClinical valueDose reductions of cabozantinibRandomized phase II clinical trialCombination immune therapyObjective response rateUpfront combination therapyPhase II clinical trialSoft tissue tumor samplesII clinical trialsClear cell RCCStandard of careDisease specific treatmentSingle agent studiesDose delaysSequential therapyOverall survivalCell RCC